Losing Its Luster

Aug 22, 2008

Derek Lowe doesn't think RNAi will ever be useful in drug therapies, mainly because "nucleic acid-based therapies are just nightmarish to administer," he says. And he's not the only one. In a post at In the Pipeline, Lowe links to a recent CNBC story that details Leerink Swann's coverage of Alnylam.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

International Scientific Societies Launch Commission on Clinical Use of Human Genome Editing
PreludeDx Receives New York State Approval for DCIS Test
River Valleys Influenced Mitochondrial Landscape Among Han Chinese Populations
Biotech Support Group, Leiden University Medical Center Ink Cancer Biomarker Research Agreement
Agendia, Imegen Ink Distribution Deal for Breast Cancer Tests in Spain, Portugal
Sage Science Wins $1.8M NIH Grant for CRISPR/Cas9 DNA Prep for Long-Read Sequencing

The Scan

GEDmatch Opts Outs

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

Noisy Signal

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

For All the Cute Doggos

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

This Week in PNAS

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.

Menu